Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-02-24
2010-06-08
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024100, C536S024310, C514S04400A, C435S006120, C435S325000, C435S375000
Reexamination Certificate
active
07732590
ABSTRACT:
Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.
REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5837542 (1998-11-01), Grimm et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6083695 (2000-07-01), Hardin et al.
patent: 6100077 (2000-08-01), Sturley et al.
patent: 6127533 (2000-10-01), Cook et al.
patent: 6284538 (2001-09-01), Monia et al.
patent: 6344548 (2002-02-01), Farese, Jr. et al.
patent: 6444427 (2002-09-01), Ludwig et al.
patent: 6512099 (2003-01-01), Omura et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6605451 (2003-08-01), Marmaro et al.
patent: 6607893 (2003-08-01), Ramharack et al.
patent: 6822141 (2004-11-01), Lardizabal et al.
patent: 7250496 (2007-07-01), Bentwich
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2002/0119138 (2002-08-01), Cases et al.
patent: 2002/0127627 (2002-09-01), Ramharack et al.
patent: 2002/0193315 (2002-12-01), Omura et al.
patent: 2003/0028923 (2003-02-01), Lardizabal et al.
patent: 2003/0073103 (2003-04-01), Ludwig et al.
patent: 2003/0100480 (2003-05-01), Smith et al.
patent: 2003/0104414 (2003-06-01), Attersand
patent: 2003/0115632 (2003-06-01), Lardizabal et al.
patent: 2003/0124126 (2003-07-01), Cases et al.
patent: 2003/0152574 (2003-08-01), Logan et al.
patent: 2003/0161831 (2003-08-01), Cases et al.
patent: 2003/0170691 (2003-09-01), Gimeno et al.
patent: 2003/0200563 (2003-10-01), Butler et al.
patent: 2003/0202968 (2003-10-01), Cases et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2004/0054177 (2004-03-01), Otake et al.
patent: 2004/0058820 (2004-03-01), Hagmann et al.
patent: 2004/0097459 (2004-05-01), Dobie et al.
patent: 2004/0122033 (2004-06-01), Nargund et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 1 308 459 (2003-05-01), None
patent: WO 00/78961 (2000-12-01), None
patent: WO 01/68848 (2001-09-01), None
patent: WO 01/77389 (2001-10-01), None
patent: WO 01/92512 (2001-12-01), None
patent: WO 02/08260 (2002-01-01), None
patent: WO/02/068595 (2002-09-01), None
patent: WO/03/053363 (2003-07-01), None
Chin, Andrew “On the Preparation and Utilization of Isolated and Purified Oligonucleotides.” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
Desai, U. J. et al., “Phenotypic Correction of Diabetic Mice by Adenovirus-Mediated Glucokinase Expression,”Diabetes(2001) 50:2287-2295.
Guo, S. et al., “par-1, a Gene Required for Establishing Polarity inC. elegansEmbryos, Encodes a Putative Ser/Thr Kinase That is Asymmetrically Distributed,”Cell(1995) 81:611-620.
Montgomery, M. K. et al., “RNA as a target of double-stranded RNA-mediated genetic interference inCaenorhabditis elegans,” Proc. Natl. Acad. Sci. USA(1998)95:15502-15507.
Stone, S. J. et al., “Lipopenia and Skin Barrier Abnormalities in DGAT2-deficient Mice,”J. Biol. Chem.(2004) 279(12):11767-11776.
Tijsterman, M. et al., “RNA Helicase MUT-14-Dependent Gene Silencing Triggered inC. elegansby Short Antisense RNAs,”Science(2002) 295:694-697.
Yu, X. X. et al., “Antisense Oligonucleotide Inhibition of DGAT2 Expression Reduced Hepatic Steatosis and Hyperlipidemia in Diet-Induced Obese Mice,”Obesity Res.(2003) NAASO's 2003 Annual Meeting, Oct. 11-15, 11:A48.
Yu, X. X. et al., “Antisense Oligonucleotide Reduction of DGAT2 Expression Improves Hepatic Steatosis and Hyperlipidemia in Obese Mice,”Hepatology(2005) 42:362-371.
The European Supplementary European Search Report dated Jul. 4, 2008 (EP 04 77 9444).
Cheng et al., “Human acyl-CoA: diacylglycerol acyltransferase is a tetrameric protein”,Biochem. J.Nov. 1, 2001 359 (pt 3) :707-714.
Ludwig et al., “DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women”,Clin. Genet.Jul. 2002 62 (1) : 687-73.
Tabata et al., “Xanthohumols, diacylglycerol acyltransferase inhibitors, from Humulus lupulus”,PhytochemistryOct. 1997 46 (4) : 683-687.
Tomoda et al., “Roselipins, inhibitors of diacylglycerol acyltransferase, produced by Gliocladium roseum KF-1040”,J. Antibiot.(Tokyo) Aug. 1999 52 (8) :689-694.
Yu et al., “Posttranscriptional control of the expression and function of diacylglycerol acyltransferase-1 in mouse adipocytes”,J. Biol. Chem.Dec. 27, 2002 277 (52) :50876-50884.
Branch et al., “A good antisense molecule is hard to find” TIBS (1998) 23:45-50.
Buhman et al., “DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis” J. Biol. Chem. (2002) 277:25474-25479.
Cases et al., “Identification of a gene encoding an acyl CoA: diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis” Proc. Natl. Acad. Sci. (1998) 95:13018-13023.
Cases et al., “Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members” J. Biol. Chem. (2001) 276:38870-38876.
Chen et al., “Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1” J. Clin. Invest. (2002) 109:1049-1055.
Chen et al., “Leptin modulates the effects of acyl CoA: diacylglycerol acyltransferase deficiency on murine fur and sebaceuous glands” J. Clin. Invest. (2002) 109:175-181.
Cheng et al., “Human acyl-CoA: diacylglycerol acyltransferase is a tetrameric protein” Biochem. J. (2001) 359:707-714.
Crooke et al., “Basic Principles of Antisense Therapeutics” Antisense Research and Application (1998) Chapter 1:1-50.
Farese et al., “Triglyceride synthesis: insights from the cloning of diacylglycerol acyltransferase” Curr. Opin. Lipidol. (2000) 11:229-234.
Final Rejection for U.S. Appl. No. 10/643,801 dated Apr. 18, 2008.
International Search Report for Int. Application No. PCT/US04/24384 dated Mar. 23, 2006.
Lardizabal et al., “DGAT2 is a new diacylglycerol acyltransferase gene family: purification, cloning, and expression in insect cells of two polypeptides from Mortierella ramanniana with diacylglycerol acyltransferase activity” J. Biol. Chem. (2001) 276:38862-38869.
Ludwig et al., “DGAT1 promotor polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women” Clin. Genet. (2002) 62:68-73.
Meegalla et al., “Concerted elevation of acyl-coenzyme A:diacylglycerol acyltransferase (DGAT) activity through independent stimulation of mRNA expression of DGAT1 and DGAT2 by carbohydrate and insulin” Biochem. Biophys. Res. Comm. (2002) 298:317-323.
Melo et al., Trends in Molecular Medicine, 2005, 11:240-250.
New England Biolabs 1998/1999 Catalog, cover page, pp. 121 and 284.
Oelkers et al., “Characterization of two human genes encoding acyl coenzyme A: cholesterol acyltransferase-related enzymes” J. Biol. Chem. (1998) 273:26765-26771.
Office Action for U.S. Appl. No. 10/643,801 dated Sep. 19, 2005.
Office Action for U.S. Appl. No. 10/643,801 dated Aug. 28, 2006.
Office Action for U.S. Appl. No. 10/643,801 dated Jan. 21, 2009.
Smith et al., “Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat” Nat. Genet. (2000) 25:87-90.
Tabata et al., “Xanthohumols, diacylglycerol acyltransferase inhibitors, from Humulus lupulus” Phytochemistry (1997) 46:683-687.
Tomoda et al., “Roselipins, inhibitors of diacylglycerol acyltra
Bhanot Sanjay
Dobie Kenneth W.
Monia Brett P.
Yu Xing-Xian
Chong Kimberly
Isis Pharmaceuticals , Inc.
LandOfFree
Modulation of diacylglycerol acyltransferase 2 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of diacylglycerol acyltransferase 2 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of diacylglycerol acyltransferase 2 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4232517